StromaBio
Sweden - SolnaBiotechnology
Focus: StromaBio is a Swedish biotech company specializing in mesenchymal stromal cell (MSC) therapies for oncology and cell therapy applications. Founded in 2018 and publicly listed, the company operates in the emerging cell therapy space with a focus on regenerative and immuno-oncology approaches.
Profile data last refreshed 21h ago · AI intelligence enriched 1w ago
Funding Stage
PUBLIC
Open Jobs
0
About StromaBio
AI assessmentNot HiringNo open roles listed right now. Follow StromaBio to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from StromaBio's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
0/9 — Limited
Company HealthSolid
Pipeline
Early-stage
0 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Open Jobs (0)
No open positions listed yet. Check their careers page directly.
Interview Prep Quick Facts
Founded: 2018
Help build intelligence for StromaBio
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.